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Mutation analysis of the 
phospholamban gene in 315 South 
Africans with dilated, hypertrophic, 
peripartum and arrhythmogenic 
right ventricular cardiomyopathies
Maryam Fish1, Gasnat Shaboodien1, Sarah Kraus1, Karen Sliwa1, Christine E. Seidman2,3, 
Michael A. Burke2,3, Lia Crotti4,5, Peter J. Schwartz1,4,5 & Bongani M. Mayosi1
Cardiomyopathy is an important cause of heart failure in Sub-Saharan Africa, accounting for up to 
30% of adult heart failure hospitalisations. This high prevalence poses a challenge in societies without 
access to resources and interventions essential for disease management. Over 80 genes have been 
implicated as a cause of cardiomyopathy. Mutations in the phospholamban (PLN) gene are associated 
with dilated cardiomyopathy (DCM) and severe heart failure. In Africa, the prevalence of PLN mutations 
in cardiomyopathy patients is unknown. Our aim was to screen 315 patients with arrhythmogenic 
right ventricular cardiomyopathy (n = 111), DCM (n = 95), hypertrophic cardiomyopathy (n = 40) and 
peripartum cardiomyopathy (n = 69) for disease-causing PLN mutations by high resolution melt analysis 
and DNA sequencing. We detected the previously reported PLN c.25C > T (p.R9C) mutation in a South 
African family with severe autosomal dominant DCM. Haplotype analysis revealed that this mutation 
occurred against a different haplotype background to that of the original North American family and 
was therefore unlikely to have been inherited from a common ancestor. No other mutations in PLN 
were detected (mutation prevalence = 0.2%). We conclude that PLN is a rare cause of cardiomyopathy 
in African patients. The PLN p.R9C mutation is not well-tolerated, emphasising the importance of this 
gene in cardiac function.
Cardiomyopathy is defined as a myocardial disease in which the heart muscle is structurally and functionally 
abnormal, without hypertension, coronary artery disease, valvular disease or congenital heart disease which is 
sufficient to cause the observed myocardial abnormality1. It is a major cause of heart disease in Sub-Saharan 
Africa, accounting for 20–30% of adults hospitalised for acute heart failure in the region2. Cardiomyopathy poses 
a challenge in Africa because of its high prevalence in resource-poor societies, the difficulty of diagnosis, the 
limited access to effective interventions and the associated high mortality3. Cardiomyopathies can be primary 
(genetic, mixed or acquired) or secondary (infiltrative, toxic or inflammatory)4.
Cardiomyopathies are known to be caused by genes that have cytoskeletal, contractile and calcium regula-
tory functions5. One of the genes implicated in cardiomyopathy is phospholamban (PLN), which encodes the 
phospholamban protein that is involved in calcium signalling and muscle contraction. Mutations in PLN have 
been associated with dilated cardiomyopathy (DCM)6–8, hypertrophic cardiomyopathy (HCM)9 and recently 
arrhythmogenic right ventricular cardiomyopathy (ARVC) in North America and Europe10, but the role of 
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PLN in Africans with cardiomyopathy is unknown11. A PLN founder mutation, PLN p.R14del, was identified in 
large European cohorts, including 10–15% of Dutch patients with ARVC or DCM, and was associated with high 
mortality and poor prognosis10,12. As this mutation arose 575–825 years ago, the possibility exists that the PLN 
p.R14del founder mutation may be present in descendants of Dutch settlers and may cause cardiomyopathy in a 
subset of individuals of European descent in Southern Africa13. The aim of this study was to determine if PLN is a 
cause of cardiomyopathy in Africans, and explore the possibility of PLN founder mutations common between the 
African population and individuals with European ancestry.
Results
Mutation screening of PLN in 315 patients with cardiomyopathy (ARVC (n = 111)14, DCM (n = 95)15, HCM 
(n = 40)16, and peripartum cardiomyopathy (PPCM) (n = 69))17 revealed the previously reported c.25C > T 
(p.R9C) mutation in a proband of European descent with severe DCM (DCM 320.1; Individual II:2)6. This muta-
tion results in the alteration of a conserved amino acid (Fig. 1A,B) from an arginine (R) to a cysteine (C) and was 
absent in 200 ethnically matched control chromosomes. No PLN mutations were detected in individuals with 
ARVC, HCM or PPCM.
Detailed investigations into the ancestry of individual DCM 320.1 pointed to an autosomal dominant inher-
itance pattern within this DCM family (Fig. 1C). The proband (DCM 320.1; II:2) had a heart transplant at the 
age of 35 years while her younger sister (DCM 320.5; II:3) was likewise affected with DCM and required a heart 
transplant at the age of 39 years. The proband’s son (DCM 320.3; III:1) developed DCM at the age of 24 years and 
underwent a heart transplant a year later. The echocardiogram showed features of DCM with a left ventricular 
ejection fraction of 20%. Coronary angiography showed patent epicardial coronary arteries, and left ventriculog-
raphy displayed a dilated left ventricle with poor systolic function. The proband’s daughter (DCM 320.4; III:3) 
was asymptomatic but the echocardiogram showed borderline dilatation of the left ventricle (left ventricular end 
diastolic dimension of 5.3 cm) and left ventricular ejection fraction of 47%. Further enquiry also revealed that 
the proband’s mother had died of a heart condition at the age of 36 years. However, we were not able to confirm 
whether this individual was affected with DCM.
Subsequent mutation screening of PLN for the available members of this family found the c.25C > T (p.R9C) 
mutation in the proband’s affected son (DCM 320.3; Individual III:1) and daughter (DCM 320.4; Individual III:3) 
Figure 1. Identification of the c.25C > T (p.R9C) PLN mutation. (A) Electropherogram showing the 
c.25C > T sequence change. (B) Multiple species protein alignment of this sequence. (C) Pedigree of family 
DCM 320 showing variant c.25C > T and individuals with DCM. SB: Stillbirth; Gender (Square – Male; Circle 
– Female); Clinical Status (Black symbol – Affected; Clear symbol – Unaffected;? – Diagnosis uncertain); 
Mutation Status ( + – c.25C > T positive; – – c.25C > T negative).
www.nature.com/scientificreports/
3Scientific RepoRts | 6:22235 | DOI: 10.1038/srep22235
as well as the proband’s affected sister (DCM 320.6;Individual II:3), reflecting segregation of the c.25C > T muta-
tion with DCM in this family.
Bioinformatic analysis tools MutationTaster, PolyPhen-2 and Align GVGD predicted the PLN c.25C > T 
(p.R9C) mutation to be disease-causing. Further, transgenic mice bearing the PLN p.R9C mutation developed 
severe DCM and underwent premature death, confirming the pathogenicity of this mutation6. Bioinformatic 
RNA tools mfold and RNAfold predicted this variant would change mRNA secondary structure whereas the 
ESEfinder tool predicted that this variant would alter serine/arginine-rich splicing factor (SRSF1 and SRSF5) 
exonic splice enhancer recognition sites.
As the PLN c.25C > T mutation was previously reported in a family of European descent by Schmitt and col-
leagues6, we wanted to ascertain if these mutations arose independently or if they were inherited from a common 
ancestor, possibly as early as the 17th century with the European colonisation of South Africa. Haplotypes were 
constructed using published microsatellite markers spanning 5.15 Mb across the PLN gene (D6S454, PLN − 200 K, 
PLN + 200 K and D6S412)13. In the DCM 320 family, the PLN c.25C > T mutation was found to be part of a 
disease-specific haplotype spanning this 5.15 Mb region (Fig. 2A). The PLN c.25C > T mutation was found to be 
part of a different haplotype spanning 1.85 Mb in the MDO DCM family described by Schmitt et al.6 (Fig. 2B).
Discussion
In the initial report of the PLN c.25C > T (p.R9C) mutation by Schmitt and colleagues6, the mutation was asso-
ciated with an autosomal dominant inheritance pattern in DCM which was characterised by increased cardiac 
chamber dimensions, decreased contractile function at 20–30 years of age and progression to heart failure within 
5–10 years after symptom onset6, a phenotype remarkably similar to that observed in the DCM 320 family. 
Similarly, in the recent report by Truszkowska and others, the PLN p.R9C mutation was detected in an individual 
with acute onset of DCM at the age of 21 years, leading to heart transplantation at 22 years of age18.
Functional analysis of the effect of the PLN p.R9C mutation on the protein and its role in the development 
of DCM revealed significant consequences of this mutation. A transgenic mouse model harbouring the p.R9C 
mutation was shown to develop DCM6. Further evidence has suggested that PLN p.R9C results in decreased 
responsiveness to β -adrenergic stimulation secondary to reduced phosphorylation by protein kinase A6,19,20. This 
results in altered calcium kinetics and aberrant contractility. The presence of severe DCM in this family with PLN 
p.R9C reinforces the importance of this mutation in the pathogenesis of DCM.
We have established that the PLN c.25C > T mutation forms part of a disease-specific haplotype spanning 
5.15 Mb across PLN in the DCM 320 family that differed from the 1.85 Mb haplotype observed in the MDO 
DCM family described by Schmitt et al.6. It is therefore unlikely that this mutation was inherited from a common 
ancestor. By contrast, the PLN p.R14del mutation, has been identified as a founder mutation in a large Dutch 
cohort of patients with ARVC, as well patients from Germany and Spain13,21. A mouse model with cardiac-specific 
overexpression of this mutation presented with DCM associated with arrhythmias, cardiac fibrosis and premature 
death8.
Although a total of 315 South African cardiomyopathy patients (ARVC, DCM, HCM, and PPCM) were 
screened in this study, only one disease-causing mutation was found in PLN (frequency of 0.2%) illustrating that 
PLN is not a common cause of cardiomyopathy in South Africa. The failure to detect PLN mutations in patients 
with PPCM is consistent with the findings of others22. To date, there are six PLN mutations (c.25C > T (p.R9C)6,18, 
Figure 2. Haplotype analysis. (A) Pedigree of the DCM 320 family. (B) Pedigree of the MDO DCM family.
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c.26G > T (p.R9L)23,24, c.26G > A (p.R9H)24, c.40_42delAGA (p.R14del)8,10,13,25,26, c.73C > T (p.R25C)27 and 
c.116T > G (p.L39X)7) that are associated with DCM, one with ARVC (c.40_42delAGA (p.R14del)10) and three 
with HCM (c.116T > G (p.L39X)9,28, c.1-77A > G29 and c.1-42C > G30) (Table 1).
While the majority of these PLN mutations have been associated with severe cardiomyopathy, only PLN muta-
tions associated with DCM meet the strict criteria to be called definitively pathogenic. These are nonsynonymous 
variants that alter a highly conserved amino acid residue across species, are absent from large numbers of healthy 
controls, demonstrate statistically significant co-segregation with affected members of a family, and are identified 
by an unbiased genetic approach. Important additional evidence comes from (1) the recapitulation of disease 
in animals engineered to express the variant, as exists for the PLN p.R9C mutation6 or (2) the same mutation is 
identified in unrelated individuals with the disease phenotype, as we have demonstrated herein for the PLN p.R9C 
mutation.
As far as we are aware, the three PLN mutations detected in patients with HCM are disease-associated and can-
not be classified as definitely pathogenic for several reasons. First, the authors who reported the PLN c.116T > G 
(p.L39X) mutation in HCM provide evidence indicating the association of this mutation with HCM in a single 
proband31. There is no apparent familial segregation of this mutation with disease. The authors also provide no 
functional evidence demonstrating the role of this mutation in disease pathogenesis. Other authors provide evi-
dence that this mutation is associated with disease in a single proband with HCM. The proband’s daughter carried 
the mutation but was unaffected with HCM, while the 3 year old granddaughter was affected with this disease28. 
The authors suggest that this may be due to incomplete penetrance associated with this mutation, but the fact that 
the affected granddaughter is so young calls this explanation into question. Also, no functional evidence is pro-
vided for the role of this mutation in DCM pathogenesis. Second, the PLN c.1-77A > G has been associated with 
HCM in a single proband29. No evidence for familial segregation or functional evidence suggesting a role of this 
mutation in HCM pathogenesis is provided. Finally, Medin et al. report the PLN c.1-42C > G variant as associated 
with disease in a family with HCM32. One of the proband’s sons was unaffected with HCM even though he carried 
the mutation, which may be explained by incomplete penetrance. However, no functional evidence suggesting 
the role of this variant in DCM pathogenesis is provided. For these reason, we classify these three variants as 
HCM-associated but not definitely pathogenic (Table 1).
In conclusion, we have identified the previously characterised c.25C > T PLN mutation that segregates with 
severe DCM in a South African kindred following the screening of 315 patients with different types of cardio-
myopathy. No PLN mutations were identified in subjects with ARVC, HCM or PPCM. PLN mutations are a rare 
cause of cardiomyopathy in South Africans which should be added to screening panel for cardiomyopathy in the 
country.
Methods
The methods were carried out in accordance with the approved guidelines of the University of Cape Town Human 
Research Ethics Committee, and they are presented in terms of samples, genetic screening, and bioinformatic 
analysis, and microsatellite analysis below.
Samples. South African patients with ARVC (n = 111; 46% of European descent), DCM (n = 95; 8% of 
European descent), HCM (n = 40; 33% of European descent) and PPCM (n = 69; 10% of European descent) 
were referred to the Cardiac Clinic in Groote Schuur Hospital, Cape Town for genetic evaluation. ARVC cases 
were enrolled in the Arrhythmogenic Right Ventricular Cardiomyopathy Registry of South Africa. The diag-
nosis of ARVC was made according to the modified criteria set by the Task Force of the Working Group on 
Myocardial and Pericardial Diseases of the European Society of Cardiology33. DCM, PPCM and HCM patients 
were diagnosed on the basis of the definitions of the European Society of Cardiology1. The details on methods of 
clinical evaluation, demographics and clinical parameters of patients enrolled in this study have been described 
previously14–17.
Variant Disease
No. of probands carrying 
variant Frequency in control chromosomes
Definitely 
Pathogenic References
c.25C > T (p.R9C) DCM 2 0/200; 0/400 Yes 6,18
c.26G > T (p.R9L) DCM 1 0/1000 Unknown 23,24,35,36
c.26G > A (p.R9H) DCM 1 0/1000 Unknown 24,36
c.40_42delAGA (p.R14del) DCM, ARVC
39 DCM, 13 ARVC10;  
1 DCM8; 1 DCM25; 101 
DCM and ARVC13;  
1 DCM26; 1 DCM24;  
1 ARVC21
1/94610; 0/13168;0/20025;6/1643413; 0/100024 Yes 8,10,13,21,24–26,37
c.73C > T (p.R25C) DCM 1 NA Unknown 27
c.116T > G (p.L39X) DCM, HCM 2 DCM7; 1 HCM28; 1 HCM9 0/5007; 0/60028; 0/2009
Yes (DCM) 
and 
Unknown 
(HCM)
7,9,28
c.1-77A > G HCM 1 0/592 Unknown 29
c.1-42C > G HCM 1 0/100 Unknown 30
Table 1.  Known PLN variants associated with cardiomyopathy.
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Blood samples were collected for molecular genetic testing. The population controls were anonymous blood 
donors from the Western Province Blood Transfusion Service who provided blood samples for DNA isolation. 
The study was approved by the Human Research Ethics Committee of the University of Cape Town, and informed 
consent was obtained from all participants. All ARVC cases included in this study had previously been screened 
for mutations in the desmosomal genes (DSP, PKP2, DSC2, DSG2 and JUP) known to cause ARVC but were 
found not to harbour any pathogenic mutations. In our screen we included 315 ARVC, DCM, HCM and PPCM 
cases with unidentified pathogenic mutations.
Genetic screening. Mutation screening of PLN included 111 ARVC, 95 DCM, 40 HCM, and 69 PPCM 
patients and was performed by high resolution melt analysis (HRM) and Sanger sequencing using the following 
primers: Forward – 5′ -CCAGGCTACCTAAAAGAAGAC-3′ ; Reverse – 5′ -TTCCTGTCTGCATGGGATG-3′ . 
HRM is proven mutation screening method with a high sensitivity and specificity34. HRM reactions were pre-
pared using 0.5U GoTaq® Flexi DNA Polymerase (Promega, Madison, WI, USA), 5X Colorless GoTaq® Flexi 
Buffer (Promega), 3 mM (final reaction concentration) MgCl2 (Promega), 0.8 μM dNTPs (final reaction concen-
tration) (Bioline, London, United Kingdom), EvaGreen dye (Biotium, Hayward, CA, USA) and 0.4 μM of each 
primer (final reaction concentration). HRM reactions were conducted using the RotorGene 6000 (Corbett Life 
Sciences – Qiagen, Venlo, Limber, Netherlands) and conditions were 95 °C for 10 minutes, 50 cycles of 95 °C for 
5 seconds, 55 °C for 10 seconds and 72 °C for 10 seconds, and a high resolution melt from 72 °C to 95 °C with 0.1 °C 
increases in temperature. Samples displaying changes in HRM profiles relative to controls were earmarked for 
purification and sequencing. HRM products were purified using Exonuclease I (New England Biolabs, Ipswich, 
MA, USA) and FastAPTM Thermosensitive Alkaline Phosphatase (Promega) using a Mastercycler® pro thermal 
cycler (Eppendorf, Hamburg, Germany); conditions were 37 °C for 1 hour and 75 °C for 15 minutes. Sequencing 
reactions were prepared using the BigDye® Direct Cycle Sequencing Kit (Applied Biosystems – Life Technologies, 
Carlsbad, CA, USA). Reaction conditions were 96 °C for 5 minutes and 25 cycles of 96 °C for 30 seconds, 50 °C 
for 15 seconds and 60 °C for 4 minutes. Sequencing products were analysed using capillary electrophoresis with 
the ABI PRISM® 3130 × l Genetic Analyser (Applied Biosystems) at the DNA Sequencing Unit (Department of 
Genetics, Stellenbosch University, Cape Town). The prevalence of variants of interest in the control population 
was determined by screening 200 ethnically matched control chromosomes by high resolution melt analysis and 
Sanger sequencing.
Bioinformatic analysis. Bioinformatic analysis of the PLN variants of interest was conducted using vari-
ous bioinformatic tools [mfold (http://mfold.rna.albany.edu/?q= mfold/RNA-Folding-Form), RNAfold (http://
rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi), ESEFinder (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.
cgi?process= home), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/www/
SIFT_seq_submit2.html), Align GVGD (http://agvgd.iarc.fr/agvgd_input.php) and MutationTaster (http://www.
mutationtaster.org/)] to assess the impact of the variants on PLN structure and function at the mRNA and protein 
levels.
Microsatellite analysis. MDO DCM DNA samples for microsatellite analysis were obtained from 
Professor Christine Seidman (Department of Genetics, Harvard Medical School, Boston, MA). The D6S45413, 
PLN −200 K13, PLN + 200 K13 and D6S41213 microsatellite markers were used to construct haplotypes for PLN. 
PCR products were run on a 2% agarose gel for verification of reaction success and product size and specific-
ity. These products were then analysed using capillary electrophoresis with the ABI PRISM® 3130 × l Genetic 
Analyser (Applied Biosystems, Foster City, CA, USA) at the Division of Human Genetics, University of Cape 
Town. Results were analysed using GeneMapper® v4.1 software (Applied Biosystems) and haplotypes were con-
structed using Cyrillic v2.0 (Cyrillic Software, United Kingdom).
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